Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5156MR)

This product GTTS-WQ5156MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets Canlupfam IL31 gene. The antibody can be applied in Canine atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Caninized
RefSeq NM_001165914.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100302725
UniProt ID Q9N0W9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5156MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11855MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ6529MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CX-191
GTTS-WQ14225MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ2976MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ745MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AAB-001
GTTS-WQ1950MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ7174MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ13754MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN 1500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW